진통 안약 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the demulcent eye drops market size is expected to increase from USD 2.28 billion in 2025 to USD 2.41 billion in 2026 and reach USD 3.31 billion by 2031, growing at a CAGR of 6.60% over 2026-2031.

This report is Segmented by Active Ingredient (Glycerin/PEG/PG Demulcents, Cellulose Derivatives, and More), Formulation (Preserved Multi-Dose, Preservative-Free Unit-Dose, Preservative-Free Multi-Dose MDPF), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Channels, and More), and Geography (North America, Europe, and More). Market Forecasts are Provided in Terms of Value (USD).

Global Demulcent Eye Drops Market Trends and Insights

Aging Populations and Prolonged Screen-time Intensify Dry Eye Episodes and Lubricant Drop Usage

An aging base and digital lifestyles expand the addressable user pool for lubricating drops beyond the traditional senior cohort. In the United States, 49.5 million adults reported vision difficulty in 2026, including 3.8 million with severe trouble, which signals sustained reliance on accessible therapies for daily symptom relief. Population data from South Korea indicate an 8.88% dry-eye prevalence over five years with higher rates among women and older adults, reinforcing the role of demulcents in supportive care pathways in universal coverage settings. Younger cohorts are contributing more to demand as screen exposure rises, with U.S. survey findings showing half of teens record 4 or more hours of non-school screen time per day and report associated health stressors that can reduce blink frequency and disrupt tear film stability. Global screen health assessments place Gen Z daily exposure at 9 hours and link heavy use to higher digital eye strain incidence, while high myopia prevalence figures in East Asia compound ocular surface stressors that increase lubricant use. Professional organizations also highlight unmet burden, with recent education partnerships underscoring the scale of dry-eye symptoms and the role of consistent at-home care.

Rapid Shift to Preservative-free Formats, Notably Multi-dose Preservative-free (MDPF) Bottles

Preservative-free multi-dose designs address the discomfort and long-term ocular risk associated with benzalkonium chloride and related agents, without reintroducing handling friction tied to unit-dose vials. Modern containers deploy one-way valves, closed-system filters, or collapsible inner reservoirs that maintain sterility for months after opening without chemical preservatives and enable frequent daily use patterns that support adherence. Product launches since 2024 have moved decisively into this space, including preservative-free multi-dose offerings with vitamin enrichment and antioxidant systems that broaden positioning at retail across major chains and online marketplaces.

European clinical practice content and clinic guidance favor preservative-free regimens for chronic users to protect corneal integrity, which nudges category mix toward MDPF formats for long-term use. Heightened sterility oversight after 2023 contamination events and follow-on actions in 2026 has further aligned regulatory signals with these packaging choices by tightening expectations on manufacturers' assurance of sterility. The demulcent eye drops market has responded with greater investment in aseptic filling and packaging technologies that scale MDPF availability across price points.

Heightened Sterility/Quality Incidents Elevate Compliance, Testing, and Recall Risks

The industry faces tighter oversight following contamination-linked outbreaks and subsequent enforcement actions that raised the bar on sterility assurance. In March 2026 regulators flagged over 3.1 million bottles for lack of sterility assurance, reinforcing concerns that some facilities had persistent microbiological control gaps despite prior warnings. Earlier in 2023, multi-state outbreaks caused severe injuries and fatalities, which catalyzed a wide review of OTC eye drop manufacturing and inspection cycles. The combined effect has been higher capital spending on aseptic equipment, more robust environmental monitoring, and mandatory third-party sterility audits that lengthen time-to-market. Smaller firms and some contract manufacturers face strain from these upgrades, which can lead to portfolio rationalization or delayed launches. The demulcent eye drops market therefore tilts toward incumbents with validated sterile production and quality systems that can absorb compliance overhead and maintain scale.

Other drivers and restraints analyzed in the detailed report include:

1. Expansion of Online/Omnichannel Pharmacy and DTC Fulfillment for OTC Eye Lubricants
2. Rising Contact Lens Wear and Post-procedure Ocular Surface Care Increase Drop Intensity
3. Limited Head-to-head Superiority, Brand Switching and Private-label Pressure Commoditize

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Cellulose derivatives held 33.63% share in 2025, reflecting a wide installed base, low per-dose cost, and consistent inclusion across pharmacy assortments. The demulcent eye drops market continues to rely on these polymers for day-to-day relief in moderate symptom clusters and for users who prefer familiar textures and predictable handling. Higher-viscosity carboxymethylcellulose can increase residence time on the ocular surface for overnight or severe-dryness regimens, while hydroxypropyl methylcellulose suits users who need clarity for immediate activity after dosing. Sodium hyaluronate is accelerating at 9.24% CAGR over 2026-2031 as high molecular weight grades lower friction, bind water effectively, and support epithelial stability, creating perceived comfort advantages over commodity polymers. Disclosures in U.S. product labels indicate that even generic CMC formulations often include hyaluronate as an inactive excipient, a signal of how the market prefers lubricity and conditioning characteristics associated with HA. In South Korea, prescribing patterns show strong use of single-use hyaluronate for sensitive eyes, aligning with long-standing clinician emphasis on preservative-free delivery.

The demulcent eye drops market now layers biomimetic excipients such as trehalose and HP-guar to extend comfort and address evaporative dryness and surface stress beyond basic lubrication. Oil-in-water emulsions and water-free vehicles are expanding roles in meibomian gland dysfunction as they stabilize the lipid layer and slow tear evaporation, which complements aqueous-focused agents. Guidelines in German practice literature recommend hyaluronic acid for dryness sensations and panthenol for irritation or surface micro-injury, pointing to an ingredient-first approach for daily relief. Company pipelines in Asia emphasize higher-concentration secretagogues and next-generation agents that can integrate with supportive demulcent regimens, and this supports continued category depth through the forecast period. he demulcent eye drops industry is positioned to balance cellulose-based volume anchors with hyaluronate-led premium tiers that reinforce overall category value without disrupting access.

Geography Analysis

North America accounted for 36.47% share in 2025 as clinicians, payers, and retailers converged on wider access to preservative-free options across OTC and prescription-adjacent formats. In the United States, population statistics show that tens of millions of adults report vision difficulty, which underscores the large base of consumers who seek accessible daily relief through lubricants. Recalls in 2023 and again in 2026 heightened public awareness of sterility standards and catalyzed more robust oversight of manufacturers, a trend that supports established brands with validated aseptic lines. Expansion investments by leading companies in the region point to ongoing commitment to domestic supply reliability and scaled throughput capacity for preservative-free lines. The demulcent eye drops market continues to reflect premiumization in product formulation and packaging with extensive presence across national retail and e-commerce.

Asia-Pacific is expected to deliver a 9.34% CAGR through 2031 as older demographics, urban lifestyles, and higher screen exposure elevate symptom intensity and frequency. Large-scale manufacturing projects in China are timed to bring substantial sterile capacity online by 2027, which aligns production with rising domestic demand for preservative-free daily-use drops. South Korea's nationwide data show elevated dry-eye prevalence, particularly among women and older age groups, which supports the use of preservative-free single-use hyaluronate in clinical practice. In India, contact-lens growth and urban air quality challenges amplify ocular surface stress and expand the need for daily lubrication products in volume-led price tiers. Japan's guidance encourages preservative-free hyaluronate in sensitive or chronic regimens, and this practice structure complements the adoption of MDPF and single-use lines across use cases. The demulcent eye drops market is prepared to balance volume growth with packaging advances that serve high-frequency users across tiered price points.

Europe balances mature demand with continued innovation in preservative-free systems and specialized formulations. Clinical guidance in Germany recommends hyaluronic acid for dryness and panthenol for irritation while cautioning against prolonged use of preservatives, especially in frequent users, which supports continued share for preservative-free ranges. Health systems differ in how they route dry-eye therapies across reimbursement channels and OTC, which results in varied mix between pharmacy-led sales and clinician-directed prescribing. Portfolio moves in Europe include acquisitions that expand local ophthalmology offerings across five major markets and broaden access to dry eye and related therapies, with integration plans aimed at improving scale and distribution efficiency. The demulcent eye drops market also benefits from research partnerships in the region designed to advance disease-modifying approaches that complement daily lubrication and comfort regimens. Together, these drivers create a stable foundation for preservative-free lines, biomimetic excipients, and dosing configurations that better match long-term symptom management.

1. Abbvie
2. AFT Pharmaceuticals
3. Alcon
4. Bausch + Lomb
5. Bayer
6. The Cooper Companies
7. I-MED Pharma inc.
8. Laboratoires Thea
9. Menicon
10. OASIS Medical
11. OCuSOFT
12. Prestige Consumer Healthcare
13. Reckitt
14. ROHTO Pharmaceutical Co.,Ltd.
15. Santen Pharmaceuticals
16. SEED Co., Ltd.
17. Sentiss
18. Similasan Corporation
19. URSAPHARM Arzneimittel GmbH
20. VISUfarma

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Aging Populations and Prolonged Screen-time Intensify Dry Eye Episodes and Lubricant Drop Usage
  • 4.2.2 Rapid Shift to Preservative-free Formats, Notably Multi-dose Preservative-free (MDPF) Bottles
  • 4.2.3 Expansion of Online/Omnichannel Pharmacy and DTC Fulfillment for OTC Eye Lubricants
  • 4.2.4 Rising Contact Lens Wear and Post-procedure Ocular Surface Care Increase Drop Intensity
  • 4.2.5 PF multi-dose Bottle Designs (one-way valve/filters) Reduce Contamination Fears and Boost Daily Use
  • 4.2.6 Biomimetic Excipients (HA/trehalose/HP-Guar) Enable Premiumization and Regimen Bundling
• 4.3 Market Restraints
  • 4.3.1 Heightened Sterility/Quality Incidents Elevate Compliance, Testing, and Recall Risks
  • 4.3.2 Limited Head-to-head Superiority; Brand Switching and Private-label Pressure Commoditize
  • 4.3.3 Trade/tariff Shocks and GMP Upgrades Inflate COGS for Demulcents and Packaging
  • 4.3.4 Capital-intensive Aseptic Filling and PF Packaging Slow Smaller Entrants and Launches
• 4.4 Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Suppliers
  • 4.7.3 Bargaining Power of Buyers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Industry Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Active Ingredient
  • 5.1.1 Glycerin / PEG / PG demulcents
  • 5.1.2 Cellulose derivatives
  • 5.1.3 Sodium hyaluronate (HA)
  • 5.1.4 Oil-based Emulsion Tears
  • 5.1.5 Polyvinyl Alcohol / Povidone
  • 5.1.6 Dextran 70 Combinations
• 5.2 By Formulation
  • 5.2.1 Preserved multi-dose
  • 5.2.2 Preservative-free unit-dose (vials)
  • 5.2.3 Preservative-free multi-dose (MDPF)
• 5.3 By Distribution Channel
  • 5.3.1 Retail Pharmacies
  • 5.3.2 Hospital Pharmacies
  • 5.3.3 Online Channels
  • 5.3.4 Ophthalmic & Optical Stores
  • 5.3.5 Supermarkets & Hypermarkets
• 5.4 By Geography
  • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
  • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
  • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 India
    • 5.4.3.3 Japan
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
  • 5.4.4 Middle East and Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East and Africa
  • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles {(includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)}
  • 6.3.1 AbbVie (Allergan)
  • 6.3.2 AFT Pharmaceuticals
  • 6.3.3 Alcon
  • 6.3.4 Bausch + Lomb
  • 6.3.5 Bayer AG
  • 6.3.6 CooperVision
  • 6.3.7 I-MED Pharma inc.
  • 6.3.8 Laboratoires Thea
  • 6.3.9 Menicon
  • 6.3.10 OASIS Medical
  • 6.3.11 OCuSOFT
  • 6.3.12 Prestige Consumer Healthcare Inc.
  • 6.3.13 Reckitt
  • 6.3.14 ROHTO Pharmaceutical Co.,Ltd.
  • 6.3.15 Santen Pharmaceutical Co., Ltd.
  • 6.3.16 SEED Co., Ltd.
  • 6.3.17 Sentiss
  • 6.3.18 Similasan Corporation
  • 6.3.19 URSAPHARM Arzneimittel GmbH
  • 6.3.20 VISUfarma

7 Market Opportunities & Future Outlook

• 7.1 White-space & unmet-need assessment